Dr Alan Robertson holds a PhD in synthetic organic chemistry from the University of Glasgow. Following a post doctoral appointment with the Nobel Laureate, Sir John Cornforth, he took a position as a research scientist with Wellcome plc (now part of the pharmaceutical company GSK) working on drug discovery research into prostaglandins and serotonin. During his time at Wellcome, he invented the anti-migraine drug, Zomig (zolmitriptan). Alan then moved to Australia working with Faulding Ltd on the development of injectable cancer drugs and then with Amrad Ltd (later to become part of CSL) on the discovery and development of a variety of new drug technologies.
Alan then assisted in the development of several early stage companies. While Head of Drug Discovery at Kinacia, he invented the antiplatelet drug KN309 that was licensed to Astra Zeneca. During this time, he was also the CEO of Praxis and Promics. Praxis later became Pharmaxis Ltd and Alan led the company as its CEO from start up in December 1999 through to March 2013, taking the company through public listings on the Australian Stock Exchange and on NASDAQ; raising more than $350 million in the US, Europe and Australia.